Hengrui Pharmaceutical (600276.SH): Revilumide tablets obtained approval notice for drug clinical trials

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for Revelumide tablets, and will conduct clinical trials for prostate cancer in the near future. Specifically, a multicenter, randomized, double-blind, placebo-controlled phase III clinical study on the efficacy and safety of reverumide combined with androgen deprivation therapy (ADT) versus placebo plus ADT for high-risk localized or high-risk biochemical recurrence (BCR) prostate cancer after radical surgery/radiotherapy.

Revelumide tablets are second-generation AR inhibitors. Compared with first-generation AR inhibitors, they have a stronger AR inhibitory effect and have no agonistic effect. The company's Revilumide tablets were approved for marketing in 2022 to treat patients with metastatic hormone-sensitive prostate cancer (MHSPC) with a high tumor burden.